Khakban, Amir
FitzGerald, J. Mark
Tavakoli, Hamid
Lynd, Larry
Ehteshami-Afshar, Solmaz
Sadatsafavi, Mohsen http://orcid.org/0000-0002-0419-7862
Funding for this research was provided by:
AstraZeneca Canada
Article History
Received: 9 May 2018
Accepted: 15 February 2019
First Online: 28 February 2019
Ethics approval and consent to participate
: This study was approved by the University of British Columbia’s Human Ethics Board (application H15–00062). All inferences, opinions, and conclusions drawn in this research are those of the authors and do not reflect the opinions or policies of the Data Steward(s).
: JMF is a member of the Global Initiative for Asthma (GINA) Executive and Science Committees. He has served on advisory boards for Novartis, Pfizer, AstraZeneca, Boehringer-Ingelheim, and Merck. He has also been a member of speakers’ bureaus for AstraZeneca, Boehringer-Ingelheim, Novartis, and Merck. He has received research funding paid directly to the University of British Columbia from AstraZeneca, Glaxo-SmithKline, Boehringer-Ingelheim, Merck, Sanofi, and Novartis. MS receives salary support from the Canadian Institutes of Health Research and Michael Smith Foundation for Health Research. He has received research funding paid directly to the University of British Columbia from AstraZeneca. Other authors have no conflict of interests to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.